Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs

Shradha Wali, Rishein Gupta, Jieh Juen Yu, Gopala Krishna Koundinya Lanka, James P. Chambers, M. Neal Guentzel, Guangming Zhong, Ashlesh K. Murthy, Bernard P. Arulanandam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We have comprehensively demonstrated using the mouse model that intranasal immunization with recombinant chlamydial protease-like activity factor (rCPAF) leads to a significant reduction in bacterial burden, genital tract pathology and preserves fertility following intravaginal genital chlamydial challenge. In the present report, we evaluated the protective efficacy of rCPAF immunization in guinea pigs, a second animal model for genital chlamydial infection. Using a vaccination strategy similar to the mouse model, we intranasally immunized female guinea pigs with rCPAF plus CpG deoxynucleotides (CpG; as an adjuvant), and challenged intravaginally with C. trachomatis serovar D (CT-D). Immunization with rCPAF/CpG significantly reduced vaginal CT-D shedding and induced resolution of infection by day 24, compared with day 33 in CpG alone treated and challenged animals. Immunization induced robust anti-rCPAF serum IgG 2 weeks following the last immunization, and was sustained at a high-level 4 weeks post challenge. Upregulation of antigen-specific IFN-Î 3 gene expression was observed in rCPAF/CpG-vaccinated splenocytes. Importantly, a significant reduction in inflammation in the genital tissue in rCPAF/CpG-immunized guinea pigs compared with CpG-immunized animals was observed. Taken together, this study provides evidence of the protective efficacy of rCPAF as a vaccine candidate in a second animal model of genital chlamydial infection.

Original languageEnglish (US)
Pages (from-to)454-460
Number of pages7
JournalImmunology and Cell Biology
Volume95
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Guinea Pigs
Peptide Hydrolases
Immunization
Animal Models
Infection
Fertility
Vaccination
Up-Regulation
Vaccines
Immunoglobulin G
Pathology
Inflammation
Gene Expression
Antigens
Serum

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Wali, S., Gupta, R., Yu, J. J., Lanka, G. K. K., Chambers, J. P., Guentzel, M. N., ... Arulanandam, B. P. (2017). Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. Immunology and Cell Biology, 95(5), 454-460. https://doi.org/10.1038/icb.2016.122

Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. / Wali, Shradha; Gupta, Rishein; Yu, Jieh Juen; Lanka, Gopala Krishna Koundinya; Chambers, James P.; Guentzel, M. Neal; Zhong, Guangming; Murthy, Ashlesh K.; Arulanandam, Bernard P.

In: Immunology and Cell Biology, Vol. 95, No. 5, 01.05.2017, p. 454-460.

Research output: Contribution to journalArticle

Wali, S, Gupta, R, Yu, JJ, Lanka, GKK, Chambers, JP, Guentzel, MN, Zhong, G, Murthy, AK & Arulanandam, BP 2017, 'Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs', Immunology and Cell Biology, vol. 95, no. 5, pp. 454-460. https://doi.org/10.1038/icb.2016.122
Wali, Shradha ; Gupta, Rishein ; Yu, Jieh Juen ; Lanka, Gopala Krishna Koundinya ; Chambers, James P. ; Guentzel, M. Neal ; Zhong, Guangming ; Murthy, Ashlesh K. ; Arulanandam, Bernard P. / Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs. In: Immunology and Cell Biology. 2017 ; Vol. 95, No. 5. pp. 454-460.
@article{e9188649d10b49908915874707d0fdb6,
title = "Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs",
abstract = "We have comprehensively demonstrated using the mouse model that intranasal immunization with recombinant chlamydial protease-like activity factor (rCPAF) leads to a significant reduction in bacterial burden, genital tract pathology and preserves fertility following intravaginal genital chlamydial challenge. In the present report, we evaluated the protective efficacy of rCPAF immunization in guinea pigs, a second animal model for genital chlamydial infection. Using a vaccination strategy similar to the mouse model, we intranasally immunized female guinea pigs with rCPAF plus CpG deoxynucleotides (CpG; as an adjuvant), and challenged intravaginally with C. trachomatis serovar D (CT-D). Immunization with rCPAF/CpG significantly reduced vaginal CT-D shedding and induced resolution of infection by day 24, compared with day 33 in CpG alone treated and challenged animals. Immunization induced robust anti-rCPAF serum IgG 2 weeks following the last immunization, and was sustained at a high-level 4 weeks post challenge. Upregulation of antigen-specific IFN-{\^I} 3 gene expression was observed in rCPAF/CpG-vaccinated splenocytes. Importantly, a significant reduction in inflammation in the genital tissue in rCPAF/CpG-immunized guinea pigs compared with CpG-immunized animals was observed. Taken together, this study provides evidence of the protective efficacy of rCPAF as a vaccine candidate in a second animal model of genital chlamydial infection.",
author = "Shradha Wali and Rishein Gupta and Yu, {Jieh Juen} and Lanka, {Gopala Krishna Koundinya} and Chambers, {James P.} and Guentzel, {M. Neal} and Guangming Zhong and Murthy, {Ashlesh K.} and Arulanandam, {Bernard P.}",
year = "2017",
month = "5",
day = "1",
doi = "10.1038/icb.2016.122",
language = "English (US)",
volume = "95",
pages = "454--460",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Chlamydial protease-like activity factor mediated protection against C. trachomatis in guinea pigs

AU - Wali, Shradha

AU - Gupta, Rishein

AU - Yu, Jieh Juen

AU - Lanka, Gopala Krishna Koundinya

AU - Chambers, James P.

AU - Guentzel, M. Neal

AU - Zhong, Guangming

AU - Murthy, Ashlesh K.

AU - Arulanandam, Bernard P.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - We have comprehensively demonstrated using the mouse model that intranasal immunization with recombinant chlamydial protease-like activity factor (rCPAF) leads to a significant reduction in bacterial burden, genital tract pathology and preserves fertility following intravaginal genital chlamydial challenge. In the present report, we evaluated the protective efficacy of rCPAF immunization in guinea pigs, a second animal model for genital chlamydial infection. Using a vaccination strategy similar to the mouse model, we intranasally immunized female guinea pigs with rCPAF plus CpG deoxynucleotides (CpG; as an adjuvant), and challenged intravaginally with C. trachomatis serovar D (CT-D). Immunization with rCPAF/CpG significantly reduced vaginal CT-D shedding and induced resolution of infection by day 24, compared with day 33 in CpG alone treated and challenged animals. Immunization induced robust anti-rCPAF serum IgG 2 weeks following the last immunization, and was sustained at a high-level 4 weeks post challenge. Upregulation of antigen-specific IFN-Î 3 gene expression was observed in rCPAF/CpG-vaccinated splenocytes. Importantly, a significant reduction in inflammation in the genital tissue in rCPAF/CpG-immunized guinea pigs compared with CpG-immunized animals was observed. Taken together, this study provides evidence of the protective efficacy of rCPAF as a vaccine candidate in a second animal model of genital chlamydial infection.

AB - We have comprehensively demonstrated using the mouse model that intranasal immunization with recombinant chlamydial protease-like activity factor (rCPAF) leads to a significant reduction in bacterial burden, genital tract pathology and preserves fertility following intravaginal genital chlamydial challenge. In the present report, we evaluated the protective efficacy of rCPAF immunization in guinea pigs, a second animal model for genital chlamydial infection. Using a vaccination strategy similar to the mouse model, we intranasally immunized female guinea pigs with rCPAF plus CpG deoxynucleotides (CpG; as an adjuvant), and challenged intravaginally with C. trachomatis serovar D (CT-D). Immunization with rCPAF/CpG significantly reduced vaginal CT-D shedding and induced resolution of infection by day 24, compared with day 33 in CpG alone treated and challenged animals. Immunization induced robust anti-rCPAF serum IgG 2 weeks following the last immunization, and was sustained at a high-level 4 weeks post challenge. Upregulation of antigen-specific IFN-Î 3 gene expression was observed in rCPAF/CpG-vaccinated splenocytes. Importantly, a significant reduction in inflammation in the genital tissue in rCPAF/CpG-immunized guinea pigs compared with CpG-immunized animals was observed. Taken together, this study provides evidence of the protective efficacy of rCPAF as a vaccine candidate in a second animal model of genital chlamydial infection.

UR - http://www.scopus.com/inward/record.url?scp=85010918183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010918183&partnerID=8YFLogxK

U2 - 10.1038/icb.2016.122

DO - 10.1038/icb.2016.122

M3 - Article

VL - 95

SP - 454

EP - 460

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 5

ER -